Navigation Links
Reexamination of T. rex verifies disputed biochemical remains
Date:7/29/2009

A new analysis of the remains of a Tyrannosaurus rex (T. rex) that roamed Earth 68 million years ago has confirmed traces of protein from blood and bone, tendons, or cartilage. The findings, scheduled for publication in the Sept. 4 issue of ACS' monthly Journal of Proteome Research, is the latest addition to an ongoing controversy over which biochemical remnants can be detected in the dino.

In the study, Marshall Bern, Brett S. Phinney and David Goldberg point out that the first analysis in 2007 of a well-preserved, fossilized T. rex bone identified traces of seven distinct protein fragments, or peptides, from collagen. That material is one of the primary components of bone, tendons and other connective tissue. However, later studies disputed that finding, suggesting that it was a statistical fluke or the result of contamination from another laboratory sample.

The scientists describe reanalysis of the T. rex data and also report finding evidence of substances found in collagen. "In summary, we find nothing obviously wrong with the Tyrannosaurus rex [analysis from 2007]," the report states. "The identified peptides seem consistent with a sample containing old, quite possibly very ancient, bird-like bone, contaminated with only fairly explicable proteins. Hemoglobin and collagen are plausible proteins to find in fossil bone, because they are two of the most abundant proteins in bone and bone marrow."


'/>"/>

Contact: Michael Woods
m_woods@acs.org
202-872-6293
American Chemical Society
Source:Eurekalert  

Page: 1

Related medicine news :

1. Immunologists identify biochemical signals that help immune cells remember how to fight infection
2. Biochemical markers for non-invasive assessment of primary biliary cirrhosis
3. Prenatal biochemical screening only detects half of chromosomal abnormalities
4. Major missed biochemical pathway emerges as important in virtually all cells
5. Scientists Spot Biochemical Sign of Depression
6. Hospital for Special Surgery Remains Top Hospital in Northeast in U.S. News & World Reports Americas Best Hospitals List for Orthopedics
7. OTC Market Is Not Largely Impacted by Recession; However, Prominent Growth Remains Only in Some Categories, According to Kline
8. TriWest Healthcare Alliance Awarded Third TRICARE Contract, Remains Health Care Contractor for Department of Defense in 21-State TRICARE West Region
9. Nicotine dependence remains prevalent despite recent declines in cigarette use
10. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
11. Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reexamination of T. rex verifies disputed biochemical remains
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... A short-term, very-high dose regimen of the immune-suppressing drug ... in most of a small group of patients studied ... disease, Johns Hopkins researchers report. The findings in nine ... suggest new ways to treat a disease that tends ...
... Bulge with Hoodia and Bitter Orange, LOS ... fatty,and unhealthy coffee creamers, Java Solutions today announces ... creamer to start your day off,with a weight-loss ... of,French vanilla and non-fat buttercream with Hoodia, a ...
... to Solantic Board, JACKSONVILLE, Fla., June 10 ... urgent care, today announced,the appointment of Tom Scully ... a General Partner with New York City Private ... largest private equity investor in,healthcare. In addition, Mr. ...
... 10 Christine Carson Filipovich, a,graduate of Venture ... Nursing Resources, Inc., was honored last month with ... Bolton School of Nursing at,Case Western Reserve University ... an alumna or alumnus "who has demonstrated,outstanding leadership ...
... no longer just for doctors as PointOne ... WAUWATOSA, Wis., June 10 PointOne Systems, ... tool, known as,RedBox Technology, will begin providing reports ... dramatic change from the industry,s focus,on hospitals, research ...
... Information technology has the power,"to transform data ... Co. executive Carly Fiorina once explained., ... Ingenious Med,s IM Quality,Measures(TM), a software package ... capture, report, and submit quality performance,metrics. Physicians ...
Cached Medicine News:Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Leaner Coffee Creamer Boosts Metabolism and Curbs Appetite 2Health News:Healthcare Veteran Joins Solantic Board of Directors 2Health News:Nursing Entrepreneur Whose Business Career Was Spurred by Venture Training is Honored with Alumna Award from Case Western Reserve University 2Health News:PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 3Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 4
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: